Sonoma Pharmaceuticals, Inc. (SNOA)
- Previous Close
0.1574 - Open
0.1574 - Bid --
- Ask 0.1595 x 100
- Day's Range
0.1505 - 0.1599 - 52 Week Range
0.1200 - 1.5200 - Volume
150,287 - Avg. Volume
1,474,200 - Market Cap (intraday)
2.482M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8200 - Earnings Date Jun 19, 2024 - Jun 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
www.sonomapharma.com9
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SNOA
Performance Overview: SNOA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNOA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNOA
Valuation Measures
Market Cap
2.46M
Enterprise Value
437.17k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.08
Price/Book (mrq)
0.37
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
-0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.23%
Return on Assets (ttm)
-19.44%
Return on Equity (ttm)
-82.87%
Revenue (ttm)
12.31M
Net Income Avi to Common (ttm)
-5.08M
Diluted EPS (ttm)
-0.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
2.41M
Total Debt/Equity (mrq)
5.75%
Levered Free Cash Flow (ttm)
-4.58M